Work

Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs14-s3-06

Authors: Katherine A Hoadley, William T Barry, Brandelyn N Pitcher, Joel S Parker, Matthew D Wilkerson, William Irvin, Norah Lynn Henry, Sara M Tolaney, Chau Dang, Ian E Krop, Donald A Berry, Elaine R Mardis, Charles M Perou, Eric P Winer, Clifford A Hudis, Lisa A Carey

Institutions: Dana-Farber Cancer Institute, Duke University, Bon Secours Health System, University of Michigan, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1635667348

Cites:

Cited by: 6

Related to: 10